Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 8/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036882 | 0.88 | FDFT1 (0.37) | CTSAMAPTHTTSMN1; SMN2LMNA | |
| SCHEMBL25753619 | 0.88 | FDFT1 (0.37) | CTSAMAPTHTTSMN1; SMN2LMNA | |
| SCHEMBL25752819 | 0.87 | CTSA (0.34) | CTSAMAPTHTTHSD17B10KDM4E | |
| SCHEMBL25753621 | 0.87 | MEN1 (0.34) | ALDH1A1HTTKAT6AKDM4ELMNA | |
| SCHEMBL24036886 | 0.87 | MEN1 (0.34) | ALDH1A1HTTKAT6AKDM4ELMNA | |
| SCHEMBL25753581 | 0.86 | CTSA (0.38) | CTSAMAPTKDM4ETSHR | |
| SCHEMBL24036721 | 0.86 | CTSA (0.38) | CTSAMAPTKDM4ETSHR | |
| SCHEMBL24036537 | 0.85 | EPHX2 (0.35) | MAPTALDH1A1HTTSMN1; SMN2PKM | |
| SCHEMBL25753637 | 0.85 | EPHX2 (0.35) | MAPTALDH1A1HTTSMN1; SMN2PKM | |
| SCHEMBL24036538 | 0.84 | BACE1 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | CTSA 4587/4885MAPT 3157/4885ALDH1A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.